The novel coronavirus SARS-CoV-2 has created an enormous challenge for laboratories and communities worldwide. To address the crisis presented by COVID-19, labs need an accurate testing method capable of cost-effectively processing large numbers of samples.
The new SARS-CoV-2 coronavirus like other types of virus, does not exclusively cause respiratory damage; in fact, neurological, cardiovascular, renal and other organ involvement has been described. Specifically, at the cardiac level, it is estimated that there is damage in 1 in 5 hospitalized patients.
Measure biomarkers of inflammation with ProcartaPlex multiplex immunoassay panels. Simultaneously quantitate up to 65 soluble immune biomarkers from a single sample. Use preconfigured chemokine and cytokine panels or select from single targets to create your own custom panel to detect and quantitate the inflammatory response.
As the global COVID-19 pandemic evolves, researchers worldwide are working hard to study the mechanisms underlying SARS-CoV-2 infection.
